A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee
- PMID: 20602715
- DOI: 10.1111/j.1533-2500.2010.00401.x
A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee
Abstract
Objective: To evaluate the efficacy and safety of duloxetine in the treatment of chronic pain due to osteoarthritis of the knee.
Methods: This was a 13-week, randomized, double-blind, placebo-controlled trial in patients meeting American College of Rheumatology clinical and radiographic criteria for osteoarthritis of the knee. At baseline, patients were required to have a ≥ 4 weekly mean of the 24-hour average pain ratings. Patients were randomized to either duloxetine 60 mg once daily (QD) or placebo. At week 7, the duloxetine dosage was increased, in a blinded fashion, to 120-mg QD in patients reporting < 30% pain reduction. The primary efficacy measure was Brief Pain Inventory (BPI) 24-hour average pain. Secondary efficacy measures included Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC); Clinical Global Impressions of Severity (CGI-S). Safety and tolerability was also assessed.
Results: Of the total (n = 256) patients, 111 (86.7%) in placebo group and 93 (72.7%) in duloxetine group completed the study. Patients treated with duloxetine had significantly (P ≤ 0.001) greater improvement at all time points on BPI average pain and had significantly greater improvement on BPI pain severity ratings (P ≤ 0.05), WOMAC total (P = 0.044) and physical functioning scores (P = 0.016), and CGI-S (P = 0.009) at the study endpoint. Frequency of treatment-emergent nausea, constipation, and hyperhidrosis were significantly higher in the duloxetine group (P ≤ 0.05). Significantly more duloxetine-treated patients discontinued the trial because of adverse events (P = 0.002).
Conclusions: Treatment with duloxetine 60 mg to 120 mg QD was associated with significant pain reduction and improved function in patients with pain due to osteoarthritis of the knee.
© 2010 Eli Lilly and Company. Pain Practice © 2010 World Institute of Pain.
Similar articles
-
A double blind, randomized, placebo controlled study to evaluate the efficacy of erythromycin in patients with knee effusion due to osteoarthritis.Int J Rheum Dis. 2009 Apr;12(1):44-51. doi: 10.1111/j.1756-185X.2009.01379.x. Int J Rheum Dis. 2009. PMID: 20374316 Clinical Trial.
-
Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study.Pain Med. 2010 May;11(5):648-57. doi: 10.1111/j.1526-4637.2010.00836.x. Epub 2010 Apr 13. Pain Med. 2010. PMID: 20546509 Clinical Trial.
-
Responsiveness of the Intermittent and Constant Osteoarthritis Pain (ICOAP) scale in a trial of duloxetine for treatment of osteoarthritis knee pain.Osteoarthritis Cartilage. 2013 May;21(5):691-4. doi: 10.1016/j.joca.2013.02.007. Epub 2013 Feb 26. Osteoarthritis Cartilage. 2013. PMID: 23485934 Clinical Trial.
-
Weight change with long-term duloxetine use in chronic painful conditions: an analysis of 16 clinical studies.Int J Clin Pract. 2011 Mar;65(3):341-9. doi: 10.1111/j.1742-1241.2011.02635.x. Int J Clin Pract. 2011. PMID: 21314871 Review.
-
New treatments for osteoarthritis.Curr Opin Rheumatol. 2013 May;25(3):310-6. doi: 10.1097/BOR.0b013e32835f69b4. Curr Opin Rheumatol. 2013. PMID: 23425965 Review.
Cited by
-
Work-related outcomes in randomized, double blind, placebo-controlled trials in osteoarthritis - are they adequately reported in journal publications? A systematic review.J Occup Med Toxicol. 2018 Oct 20;13:32. doi: 10.1186/s12995-018-0215-8. eCollection 2018. J Occup Med Toxicol. 2018. PMID: 30377437 Free PMC article.
-
The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports.Drug Healthc Patient Saf. 2013 Nov 25;5:211-9. doi: 10.2147/DHPS.S45445. eCollection 2013. Drug Healthc Patient Saf. 2013. PMID: 24348072 Free PMC article.
-
Drugs in Development to Manage Acute Pain.Drugs. 2025 Jan;85(1):11-19. doi: 10.1007/s40265-024-02118-0. Epub 2024 Nov 19. Drugs. 2025. PMID: 39560856 Review.
-
Does sex affect the efficacy of systemic pharmacological treatments of pain in knee osteoarthritis? A systematic review.Osteoarthr Cartil Open. 2024 Feb 10;6(1):100438. doi: 10.1016/j.ocarto.2024.100438. eCollection 2024 Mar. Osteoarthr Cartil Open. 2024. PMID: 38375468 Free PMC article. Review.
-
The short-term effect and safety of duloxetine in osteoarthritis: A systematic review and meta-analysis.Medicine (Baltimore). 2019 Nov;98(44):e17541. doi: 10.1097/MD.0000000000017541. Medicine (Baltimore). 2019. PMID: 31689755 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical